Article Text

Download PDFPDF
Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab
  1. J M Ruiz-Moreno1,2,
  2. J A Montero2,3,
  3. F Gomez-Ulla4,5
  1. 1
    Department of Ophthalmology, Castilla La Mancha University, Albacete, Spain
  2. 2
    Alicante Institute of Ophthalmology, VISSUM, Vitreo-Retinal Unit, Alicante, Spain
  3. 3
    Pio del Rio Hortega University Hospital, Valladolid, Spain
  4. 4
    Technological Institute of Ophthalmology, Santiago de Compostela, Spain
  5. 5
    Complejo Hospitalario Universitario, Santiago de Compostela, Spain
  1. Correspondence to Dr J M Ruiz-Moreno, Departamento de Ciencias Médicas, Facultad de Medicina, Avda de Almansa, 14, 02006 Albacete, Spain; josemaria.ruiz{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Myopic maculopathy is the main cause of vision loss among highly myopic patients, and the leading aetiology of subfoveal choroidal neovascularisation (CNV) among patients <50 years old. Different therapeutic approaches have been used to treat myopic CNV, including argon laser photocoagulation, surgery and photodynamic therapy (PDT). New anti-angiogenic drugs have been used to treat subfoveal CNV secondary to high myopia.1 2

The purpose of this study is to report the influence of previous PDT on the visual outcome of subfoveal and juxtafoveal CNV in highly myopic patients treated by intravitreal bevacizumab (IB).

Twenty-nine eyes from 28 highly myopic patients with subfoveal and juxtafoveal CNV were treated by three-monthly intravitreal injections of 1.25 mg bevacizumab. Patients on treatment by PDT were started on IB if they were losing visual acuity or CNV did not respond to PDT.

Best …

View Full Text


  • Funding This study was supported in part by a grant from the Spanish Ministry of Health, Instituto de Salud Carlos III, Red Temática de Investigación Cooperativa en Salud “Patología ocular del envejecimiento, calidad visual y calidad de vida” (RD07/0062/0119).

  • Competing interests None declared. The authors have neither proprietary nor financial interest in the devices and drugs described in this paper.

  • Ethics approval The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. Individualised approval from the National Ministry of Health was obtained prior to the procedure.

  • Patient consent Written informed consent was obtained. Patients were informed about the off-label condition of this therapy and about the possible risks of pregnancy and in utero exposure.

  • Provenance and peer review Not commissioned; externally peer reviewed.